Forward-looking statements and non-GAAP financial measures This presentation contains forward-looking statements relating to our plans and expectations including, without limitation, statements regarding the future performance and operations of our business, expectations regarding stabilization in demand, and expected growth from our digital investments, all of which are subject to risks and uncertainties. Such statements are based on management's expectations and assumptions as of the date of this presenta ...

Financial Performance - Q3 2025 - Q3 average paid worksite employees increased by 1%[8] - Adjusted EBITDA decreased by 74%[11] - Adjusted EPS decreased by 151%[11] - Operating expenses decreased by 4% compared to Q3 2024[13] Financial Performance - YTD September 2025 - Average paid worksite employees increased by 1%[15] - Adjusted EBITDA decreased by 42%[18] - Adjusted EPS decreased by 54%[18] Balance Sheet and Cash Flow - Adjusted Cash was $120 million as of September 30, 2025[20] - Total Debt was $369 million as of September 30, 2025[20] - Adjusted EBITDA was $144 million YTD September 30, 2025[20] Q4 and FY 2025 Outlook - Q4 2025 Adjusted EBITDA is projected at $(25) million, a decrease of 209% year-over-year[22] - FY 2025 Adjusted EBITDA is projected between $119 million and $153 million, a decrease of 56% to 43% year-over-year[22] - FY 2025 Adjusted EPS is projected between $0.84 and $1.47, a decrease of 77% to 59% year-over-year[22]

Q3 2025 Financial Performance - Revenue reached $310.7 million, a 34.2% year-over-year increase[7, 11] - Contribution Profit was $98.3 million, up 22.8% year-over-year[7, 11] - Adjusted EBITDA increased to $35.9 million, representing a 45.9% year-over-year growth[7, 11] - Net Income increased significantly to $22.6 million, a 53.4% increase compared to Q3 2024[11] - Earnings Per Share (EPS) rose to $0.17, a 41.7% increase from $0.12 in Q3 2024[11] Additional Financial Data - Cash and Cash Equivalents increased to $291.5 million, an 8.0% increase compared to Q2 2025[14] - Free Cash Flow was $25.7 million, a 14.2% increase compared to Q2 2025[14] Q4 2025 and FY 2025 Financial Guidance - The company projects Q4 2025 revenue between $307 million and $312 million[16] - Revised FY 2025 revenue guidance is between $1,173 million and $1,178 million, representing a 4.3% increase from prior guidance and a 34.9% growth versus FY 2024 midpoint[16] - Revised FY 2025 Contribution Profit guidance is between $378 million and $380 million, representing a 2.2% increase from prior guidance and a 21.5% growth versus FY 2024 midpoint[16] - Revised FY 2025 Adjusted EBITDA guidance is between $132 million and $134 million, representing a 6.4% increase from prior guidance and a 41.2% growth versus FY 2024 midpoint[16]

Upwork Investor Presentation November 2025 1 Safe Harbor Statement This presentation of Upwork Inc. (together with its wholly owned subsidiaries, the "Company," "we," "us," or "our") contains "forward-looking" statements within the meaning of the federal securities laws. Forward-looking statements include all statements other than statements of historical fact, including any statements regarding our future operating results and financial position, including expected financial results for the fourth quarter ...

Inspire Medical Systems, Inc. November 2025 NYSE: INSP Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ''may,'' ''will,'' ''should,'' ''expect,'' ''plan,'' ''anticipate,'' ''could,'' "future," "outlook," ''intend,'' ''target,'' ''project,'' ''contemplate ...

Our Purpose: We employ nuclear technology to solve some of the world's most important problems Our Mission: We provide safe and effective nuclear solutions for global security, clean energy, environmental remediation, nuclear medicine, and space exploration Commitment to innovation, operational excellence, a strong safety record, and a focus on ensuring the highest ESG standards BWX Technologies, Inc. ("BWXT") cautions that statements in this presentation that are forward-looking and provide other than hist ...

Company Overview - The company operates one of the largest online insurance customer acquisition and distribution platforms[14] - The platform leverages over 4 billion consumer data points[14, 21] - The company has a diversified distribution model with approximately 60 carriers and 6,000 third-party agents[14] Market Opportunity - The P&C distribution and advertising spend market is estimated at $117 billion annually[10, 16] - Digital advertising spend within the P&C insurance market is $7 billion[16] - The company's estimated share of the P&C distribution and advertising spend market is less than 1%[17] - The estimated digital advertising spend growth in the U S P&C Insurance Market is approximately 15%[17] Financial Performance - Q3 2025 total revenue grew 20% year-over-year to $173.9 million[31, 43] - Auto insurance revenue in Q3 2025 increased 21% year-over-year to $157.6 million[43] - Home/Renters insurance revenue in Q3 2025 increased 15% year-over-year to $16.3 million[43] - Q3 2025 Adjusted EBITDA increased 33% year-over-year to $25.1 million, with an Adjusted EBITDA margin of 14.4%[31]

Equity Investor Presentation Third Quarter 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Farmer Mac's plans, objectives, expectations, beliefs and intentions and other statements including words such as "may," "likely," "believe," "expect," "consider," "intend," "should," "estimate," "continue," and "commit," or the negative o ...

Medifast® Q3 2025 Earnings Supplement © 2025 Medifast, Inc. All Rights Reserved. 2 Medifast® Q3 2025 Highlights Revenue and EPS at upper end of guidance range Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phras ...

Financial Performance - Q3 2025 total revenues reached $3.08 billion, representing an 11% year-over-year growth[5,45] - TRIKAFTA/KAFTRIO contributed $2.65 billion in Q3 2025[45] - ALYFTREK generated $247 million in revenue during Q3 2025[45] - CASGEVY revenues were $17 million in Q3 2025 and are expected to exceed $100 million for the full year 2025[45,32] - JOURNAVX revenues were $20 million in Q3 2025[45] - Non-GAAP operating income was $1.38 billion with a 45% margin in Q3 2025[45] - Non-GAAP net income was $1.24 billion, or $4.80 per diluted share in Q3 2025[45] - The company refined its 2025 revenue guidance to $11.9-12.0 billion and non-GAAP OpEx to $5.0-5.1 billion, while lowering the tax rate guidance to 17%-18%[8] Pipeline and Approvals - ALYFTREK is now approved in the U S, U K, European Union, Canada, New Zealand, and Switzerland for patients aged 6 and older[9,26] - TRIKAFTA pivotal study in 12 to <24-month-old children completed, showing a mean sweat chloride reduction of more than 70 mmol/L from baseline through week 24[8]